Abstract: The present application shows the relationship between variations in the amino acid sequence of histone proteins, more specifically the H3.3 protein, and proliferation-associated disorders. Herewith provided are predictive methods, commercial packages, therapeutic methods and screening methods based on this relationship.

Abstract: Described is a compound capable of reducing or inhibiting (a) the biological activity of branched-chain-aminotranferase-1 (BCAT1) or (b) the expression of the gene encoding BCAT1 for use in a method of treating a neoplasia. A preferred compound is 1-(aminomethyl) cyclohexaneacetic acid (gabapentin).

Abstract: Described is a compound capable of reducing or inhibiting (a) the biological activity of branched-chain-aminotrans-ferase-1 (BCATI) or (b) the expression of the gene encoding BCATI for use in a method of treating a neoplasia. A preferred compound is 1-(aminomethyl)cyclohexaneacetic acid (gabapentin).

Abstract: Described is a compound capable of reducing or inhibiting (a) the biological activity of branched-chain-aminotranferase-1 (BCAT1) or (b) the expression of the gene encoding BCAT1 for use in a method of treating a neoplasia. A preferred compound is 1-(aminomethyl) cyclohexaneacetic acid (gabapentin).

Abstract: The present application shows the relationship between variations in the amino acid sequence of histone proteins, more specifically the H3.3 protein, and proliferation-associated disorders. Herewith provided are predictive methods, commercial packages, therapeutic methods and screening methods based on this relationship.

Abstract: Described is a compound capable of reducing or inhibiting (a) the biological activity of branched-chain-aminotranferase-1 (BCAT1) or (b) the expression of the gene encoding BCAT1 for use in a method of treating a neoplasia. A preferred compound is 1-(aminomethyl) cyclohexaneacetic acid (gabapentin).

Abstract: The present invention relates to the significant role of ADAM 12, ADAM 12-L, and ADAM 12-S in preeclampsia and related disorders. The invention further relates to the use of said genes and gene products, ligands binding to those, and modulators of activity of the gene products in diagnosis and treatment of preeclampsia and related syndromes. The invention also relates to the use of further genes and combinations thereof in diagnosis of preeclampsia and related syndromes.

Abstract: Described are methods and compounds for diagnosis and therapy of subsets of cell proliferative disorders which are characterized by resistance to TRAIL induced apoptosis. Examples of such diseases are B-cell chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and prostate cancer. Furthermore, methods for identifying drugs which are suitable for treatment of such diseases are described.

Abstract: The present invention relates to the significant role of ADAM 12, ADAM 12-L, and ADAM 12-S in preeclampsia and related disorders. The invention further relates to the use of said genes and gene products, ligands binding to those, and modulators of activity of the gene products in diagnosis and treatment of preeclampsia and related syndromes. The invention also relates to the use of further genes and combinations thereof in diagnosis of preeclampsia and related syndromes.

Abstract: This disclosure relates to a method of specifically decorating selected mammalian chromosomes and of detecting, identifying and and/or quantitating selected individual chromosomes, by means of chromosomal in situ suppression (CISS) hybridization. The method is useful in analyzing cells for the occurrence of chromosomes, chromosome fragments or chromosome aberrations.

Abstract: A method of determining the relative number of nucleic acid sequences in test cells which provides for a high resolution during comparative genomic hybridization by keeping all components separate from each other and selecting target nucleic acids which have a high resolution capability for determining genomic imbalances in the test cells and which facilitate a screening of the test cells for over- or under-expression of individual genes.

Abstract: The present invention relates to a method and a program for the comparative, automatic classification of tumours based on chromosomal aberration patterns. The method for automatically classifying tumours according to the present invention particularly comprises the steps of providing a data base with tumour data of different tumour types and automatically generating rules with which the tumour data are assigned to a plurality of tumour types.

Abstract: The present invention relates to a process for identifying numerical changes in cell DNA, comprising the following steps:

Abstract: A method of determining the relative number of nucleic acid sequences in test cells which provides for a high resolution during comparative genomic hybridization by keeping all components separate from each other and selecting target nucleic acids which have a high resolution capability for determining genomic imbalances in the test cells and which facilitate a screening of the test cells for over- or under-expression of individual genes.

Abstract: This disclosure relates to a method of specifically decorating selected mammalian chromosomes and of detecting, identifying and and/or quantitating selected individual chromosomes, by means of chromosomal in situ suppression (CISS) hybridization. The method is useful in analyzing cells for the occurrence of chromosomes, chromosome fragments or chromosome aberrations.

Abstract: A method of determining the relative number of nucleic acid sequences in test cells which provides for a high resolution during comparative genomic hybridization by keeping all components separate from each other and selecting target nucleic acids which have a high resolution capability for determining genomic imbalances in the test cells and which facilitate a screening of the test cells for over- or under-expression of individual genes.

Abstract: A method is disclosed for determining the chromosomal identity of a sample of genomic DNA. The genomic DNA is amplified and labeled by polymerase chain reaction using primers substantially complementary to interspersed repetitive DNA sequences. The amplified and labeled genomic DNA fragments are then contacted with chromosomal DNA of known identity under conditions in which the chromosome-specific, but not the interspersed repetitive DNA sequences, of the amplified and labeled genomic DNA fragments are available for hybridization. Specific hybridization to chromosomal DNA of known identity determines the chromosomal identity of the sample of genomic DNA.

Abstract: A method is disclosed for determining the chromosomal identity of a sample of genomic DNA. The genomic DNA is amplified and labeled by polymerase chain reaction using primers substantially complementary to interspersed repetitive DNA sequences. The amplified and labeled genomic DNA fragments are then contacted with chromosomal DNA of known identity under conditions in which the chromosome-specific, but not the interspersed repetitive DNA sequences, of the amplified and labeled genomic DNA fragments are available for hybridization. Specific hybridization to chromosomal DNA of known identity determines the chromosomal identity of the sample of genomic DNA.